MAZE

Business Context and Reporting Period

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecule precision medicines for renal, cardiovascular, and metabolic diseases using its proprietary Compass platform. This Form 10-Q covers the quarterly period ended March 31, 2025. During this period, the Company completed its Initial Public Offering (IPO) in February 2025, converting all outstanding redeemable convertible preferred stock into common stock.

Key Financial Metrics

Material Changes vs. Prior Period

• Capital Structure Transformation: In February 2025, the Company completed its IPO, issuing 8.75 million shares at $16.00 per share for net proceeds of approximately $127.8 million. Concurrently, all outstanding redeemable convertible preferred stock (approx. 297 million shares) automatically converted into 32.6 million shares of common stock.
• Liquidity Improvement: Cash and cash equivalents increased from $196.8 million at December 31, 2024, to $294.4 million at March 31, 2025, primarily driven by IPO proceeds.
• Expense Growth: Total operating expenses increased by $7.4 million (26%) compared to Q1 2024. Research and Development (R&D) expenses rose by $5.7 million, driven by a $3.1 million increase in clinical trial expenses for lead programs MZE829 (Phase 2) and MZE782 (Phase 1).
• Interest Income: Interest and other income, net, increased significantly to $2.6 million from $0.3 million in the prior year, reflecting higher cash balances from the IPO and prior license agreements.
• Elimination of Fair Value Loss: The Company recorded a $4.8 million loss in Q1 2024 related to the change in fair value of convertible promissory notes. This item was absent in Q1 2025 as the notes converted to preferred stock in November 2024.

Guidance, Outlook, and Risks

• Outlook: Management expects to incur significant and increasing operating losses for the foreseeable future. The Company believes its cash position of $294.4 million is sufficient to fund operations for at least one year from the filing date.
• Development Milestones: The Company initiated a Phase 2 trial for MZE829 in November 2024 (first patient dosed February 2025) and expects to report initial proof of concept data in Q1 2026. A Phase 1 trial for MZE782 was initiated in September 2024.
• Revenue Strategy: The Company has no product revenue and does not expect to generate commercial sales revenue in the foreseeable future. Future revenue is expected to come from licensing milestones and royalties, including significant potential payments from agreements with Shionogi ($150M upfront received in 2024), Trace Neuroscience, and Neurocrine.
• Key Risks:
  • Capital Requirements: Substantial additional capital will be required to advance clinical trials and operations; failure to raise funds could force delays or program reductions.
  • Development Uncertainty: Clinical trials are lengthy and expensive with uncertain outcomes; failure to demonstrate safety or efficacy would materially harm the business.
  • Third-Party Reliance: The Company relies on third-party CROs and CMOs (including some in China) for manufacturing and trials, exposing it to supply chain and regulatory risks (e.g., BIOSECURE Act).
  • Intellectual Property: Success depends on obtaining and maintaining patent protection, which is uncertain and costly.

Investor Verification Checklist

• Verify the specific timelines and enrollment status for the Phase 2 trial of MZE829 and Phase 1 trial of MZE782.
• Confirm the terms and potential milestone triggers in the Shionogi, Trace, and Neurocrine license agreements.
• Assess the Company's burn rate and runway given the $294.4 million cash balance and expected increase in R&D spend.
• Review the Company's reliance on Chinese contract manufacturers and potential exposure to the BIOSECURE Act or similar trade restrictions.
• Monitor the status of the $50.0 million revolving line of credit and any potential drawdowns or covenant compliance issues.